172 related articles for article (PubMed ID: 20735140)
61. Screening novel, potent multidrug-resistant modulators from imidazole derivatives.
Chen LM; Wu XP; Ruan JW; Liang YJ; Ding Y; Shi Z; Wang XW; Gu LQ; Fu LW
Oncol Res; 2004; 14(7-8):355-62. PubMed ID: 15301426
[TBL] [Abstract][Full Text] [Related]
62. 6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers.
Braconi L; Bartolucci G; Contino M; Chiaramonte N; Giampietro R; Manetti D; Perrone MG; Romanelli MN; Colabufo NA; Riganti C; Dei S; Teodori E
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):974-992. PubMed ID: 32253945
[TBL] [Abstract][Full Text] [Related]
63. Synthesis and biological evaluation of bifendate derivatives bearing 6,7-dihydro-dibenzo[c,e]azepine scaffold as potential P-glycoprotein and tumor metastasis inhibitors.
Gu X; Jiang Y; Qu Y; Chen J; Feng D; Li C; Yin X
Eur J Med Chem; 2018 Feb; 145():379-388. PubMed ID: 29335204
[TBL] [Abstract][Full Text] [Related]
64. Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.
Dong J; Qin Z; Zhang WD; Cheng G; Yehuda AG; Ashby CR; Chen ZS; Cheng XD; Qin JJ
Drug Resist Updat; 2020 Mar; 49():100681. PubMed ID: 32014648
[TBL] [Abstract][Full Text] [Related]
65. Novel (-)-arctigenin derivatives inhibit signal transducer and activator of transcription 3 phosphorylation and P-glycoprotein function resensitizing multidrug resistant cancer cells in vitro and in vivo.
Yu KH; Kuo CY; Wu IT; Chi CH; Tsai KC; Kuo PC; Zeng JW; Hung CC; Hung HY
Eur J Pharmacol; 2023 Dec; 960():176146. PubMed ID: 37884184
[TBL] [Abstract][Full Text] [Related]
66. Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer.
Mohana S; Ganesan M; Agilan B; Karthikeyan R; Srithar G; Beaulah Mary R; Ananthakrishnan D; Velmurugan D; Rajendra Prasad N; Ambudkar SV
Mol Biosyst; 2016 Jul; 12(8):2458-70. PubMed ID: 27216424
[TBL] [Abstract][Full Text] [Related]
67. Synthesis of 2-methyl N10-substituted acridones as selective inhibitors of multidrug resistance (MDR) associated protein in cancer cells.
Mayur YC; Ahmad O; Prasad VV; Purohit MN; Srinivasulu N; Kumar SM
Med Chem; 2008 Sep; 4(5):457-65. PubMed ID: 18782042
[TBL] [Abstract][Full Text] [Related]
68. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
69. In silico study of desmosdumotin as an anticancer agent: homology modeling, docking and molecular dynamics simulation approach.
Gadhe CG; Kothandan G; Cho SJ
Anticancer Agents Med Chem; 2013 Dec; 13(10):1636-44. PubMed ID: 23796247
[TBL] [Abstract][Full Text] [Related]
70. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
[TBL] [Abstract][Full Text] [Related]
71. Indoloquinoxaline compounds that selectively antagonize P-glycoprotein.
Smith CD; Myers CB; Zilfou JT; Smith SN; Lawrence DS
Oncol Res; 2000; 12(5):219-29. PubMed ID: 11417747
[TBL] [Abstract][Full Text] [Related]
72. Design, synthesis and biological evaluation of stereo- and regioisomers of amino aryl esters as multidrug resistance (MDR) reversers.
Teodori E; Contino M; Riganti C; Bartolucci G; Braconi L; Manetti D; Romanelli MN; Trezza A; Athanasios A; Spiga O; Perrone MG; Giampietro R; Gazzano E; Salerno M; Colabufo NA; Dei S
Eur J Med Chem; 2019 Nov; 182():111655. PubMed ID: 31494468
[TBL] [Abstract][Full Text] [Related]
73. 5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance.
Ruchelman AL; Houghton PJ; Zhou N; Liu A; Liu LF; LaVoie EJ
J Med Chem; 2005 Feb; 48(3):792-804. PubMed ID: 15689163
[TBL] [Abstract][Full Text] [Related]
74. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment.
Pérez-Tomás R
Curr Med Chem; 2006; 13(16):1859-76. PubMed ID: 16842198
[TBL] [Abstract][Full Text] [Related]
75. N,N-bis(cyclohexanol)amine aryl esters: the discovery of a new class of highly potent inhibitors of transporter-dependent multidrug resistance (MDR).
Teodori E; Dei S; Martelli C; Scapecchi S
Curr Top Med Chem; 2010; 10(17):1715-31. PubMed ID: 20645921
[TBL] [Abstract][Full Text] [Related]
76. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2.
Juvale K; Stefan K; Wiese M
Eur J Med Chem; 2013 Sep; 67():115-26. PubMed ID: 23851114
[TBL] [Abstract][Full Text] [Related]
77. Development of a novel class of tubulin inhibitor from desmosdumotin B with a hydroxylated bicyclic B-ring.
Nakagawa-Goto K; Oda A; Hamel E; Ohkoshi E; Lee KH; Goto M
J Med Chem; 2015 Mar; 58(5):2378-89. PubMed ID: 25695315
[TBL] [Abstract][Full Text] [Related]
78. Multidrug resistance transporters and modulation.
Tan B; Piwnica-Worms D; Ratner L
Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
[TBL] [Abstract][Full Text] [Related]
79. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
80. Design, synthesis and biological evaluation of N-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)-4-oxo-3,4-dihydrophthalazine-1-carboxamide derivatives as novel P-glycoprotein inhibitors reversing multidrug resistance.
Qiu Q; Zhou J; Shi W; Kairuki M; Huang W; Qian H
Bioorg Chem; 2019 May; 86():166-175. PubMed ID: 30710850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
